Overexpression of cathepsin-D in primary breast cancer has been associated with rapid development of clinical metastasis. To investigate the role of this protease in breast cancer growth and progression to metastasis, we stably transfected a highly metastatic human breast cancer cell line, MDA-MB-231, with a plasmid containing either the full-length cDNA for cathepsin-D or a 535 bp antisense cathepsin-D cDNA fragment. Clones expressing antisense cathepsin-D cDNA that exhibited a 70 -80% reduction in cathepsin-D protein, both intra-and extracellularly compared to controls, were selected for further experiments. These antisense-transfected cells displayed a reduced outgrowth rate when embedded in a Matrigel matrix, formed smaller colonies in soft agar and presented a significantly decreased tumor growth and experimental lung metastasis in nude mice compared with controls. However, manipulating the cathepsin-D level in the antisense cells has no effect on their in vitro invasiveness. These studies demonstrate that cathepsin-D enhances anchorage-independent cell proliferation and subsequently facilitates tumorigenesis and metastasis of breast cancer cells. Our overall results provide the first evidence on the essential role of cathepsin-D in breast cancer, and support the development of a new cathepsin-D-targeted therapy.
Introduction
Proteases are generally assumed to play a major role in the metastasis process by favoring the escape of cancer cells from the primary site following the breakdown of connective barriers formed by extra-cellular matrices (Liotta et al., 1986) . While this invasion process constitutes the most studied area of protease action, there is an increasing body of evidences that proteases could also favor the growth of cancer cells at both primary and metastatic sites (reviewed by Chambers and Matrisian, 1997; Edwards and Murphy, 1998) . It was recently reported that the alteration of metalloproteinase activity by over-expression of either the enzyme or the TIMP2 tissue-specific inhibitor modulated cell growth (Stetler-Stevenson, 2001 ). The clinical issue of these findings is to prevent the mitogenic action of protease by specific inhibitors such as metalloproteinase inhibitors (Hidalgo and Eckhardt, 2001) .
The lysosomal aspartyl proteinase, cathepsin-D (cath-D), is over-expressed and hyper-secreted by carcinoma cells (Rochefort et al., 1987) . Many independent clinical studies have shown that the cath-D level in primary breast cancer cytosol is an independent prognostic parameter correlated with the incidence of clinical metastasis and shorter survival (reviewed by Rochefort, 1992; Ferrandina et al., 1997; Foekens et al., 1999) . The direct role of cath-D in cancer metastasis was first demonstrated in rat tumor cells in which transfectioninduced cath-D over-expression increased their metastatic potential in vivo (Garcia et al., 1990; Liaudet et al., 1994) . In this rat tumor model, the cath-D mechanism responsible for metastasis stimulation seemed to have a positive effect on cell proliferation, favoring the growth of micro-metastases, rather than increasing the invasive potential (Garcia et al., 1990; Liaudet et al., 1994 Liaudet et al., , 1995 Glondu et al., 2001) .
In breast cancer cells, so far there has been no convincing evidence concerning cath-D action. Some reports have described that the exogenous addition of purified pro-cath-D increased the growth of breast cancer cells on plastic (Vignon et al., 1986; Fusek and Vetvicka, 1994) . However, these results were not confirmed by another group (Stewart et al., 1994) . Until now, there have been no reported attempts to down-regulate cath-D protein for the purpose of unravelling its mechanism of action in breast cancer.
In this study, we reduced cath-D expression in highly metastatic MDA-MB-231 breast cancer cells by stable transfection of antisense cath-D cDNA. In antisense cath-D transfected cells, in vitro anchorage-independent growth, tumorigenicity and the lung colonization in nude mice were significantly decreased as compared to mock-transfected cells. This report provides a first evidence on the involvement of cath-D as a rate limiting factor in the growth of metastatic breast cancer cells.
Results

Selection of stable MDA-MB-231 cell lines with reduced cath-D expression
A 2 kb cDNA encoding the full-length human cath-D and a 535 bp cath-D cDNA fragment containing the first 253 nucleotides and the last 282 nucleotides of human cath-D cDNA with a 1503 nucleotide deletion in its central part, were cloned in an antisense orientation into the pSG1 mammalian expression vector ( Figure 1a) . The two antisense cath-D constructs were stably co-transfected with a hygromycin-resistance selection vector in order to reduce the level of endogenous cath-D expression in the highly metastatic MDA-MB-231 breast cancer cell line. Control cells were transfected with pSG1 vector alone. Hygromycinresistant clones were screened for human pro-cath-D secretion using an immunoradiometric assay with monoclonal anti-human cath-D antibodies (Garcia et al., 1985) . With the full-length antisense cath-D construct, we isolated 35 clones with a 26.5% mean reduction in the pro-enzyme secretion compared to that of the 36 mock-transfected clones (Figure 1b) . With the antisense cath-D-AvaI fragment construct, the efficiency of the pro-cath-D secretion inhibition was improved since a 41.8% reduction in the pro-enzyme secretion was observed in the 44 isolated clones ( Figure  1b) .
All antisense clones presenting a minimum fourfold decrease in cath-D secretion as compared to control clones were also assayed for their intracellular cath-D concentration. We selected two antisense cath-D-AvaI cell lines (AVA21 and AVA77) producing 70 -80% less cath-D, both intra-and extracellularly, as compared to two mock-transfected cell lines (CB4 and CB6) ( Figure  1c ). The cath-D concentration detected in cell extracts from AVA21 and AVA77 antisense cell lines were respectively 5.8+1.3 and 6.9+0.8 ng/mg DNA, corresponding to approximately 12+2 pmoles/mg cytosol protein, which is significantly lower than the median value (50 pmoles/mg cytosol protein) used as a prognostic cut-off level in primary breast cancer (Rochefort, 1992; Ferrandina et al., 1997; Foekens et al., 1999) . By contrast, the cellular cath-D concentrations for CB4 and CB6 control cell lines were respectively 23.4+1.3 and 35.6+3 ng/mg DNA, corresponding to approximately 56+4 pmoles/mg cytosol protein, which is over the median value in breast cancer. The amount of secreted pro-cath-D was similar in AVA21 and AVA77 antisense cells, e.g. 0.85 to 1.3 ng/mg DNA/24 h, corresponding to a concentration of 1.5 nM pro-cath-D in the extracellular medium. Conversely, in control cells, the amount of the secreted pro-enzyme was fivefold higher, e.g. 3.9 to 5.2 ng/mg DNA/24 h, corresponding to a concentration of 7 nM pro-cath-D in the medium.
In vitro growth in tri-dimensional matrices of antisense cath-D transfected cells
We first studied the growth of cell lines embedded in Matrigel, a reconstituted basement membrane ( Figure  2 ). As noted by phase contrast microscopy after 3 days of culture, AVA21 and AVA77 antisense cells still had Numbering is according to Faust et al. (1985) . The expression of human antisense cath-D RNA is under the control of the SV40 early gene promoter region including the tandemly repeated 72 bp enhancer segments and the SV40 late promoter. The pSG1 plasmid contains the donor and acceptor splice sites, the polyadenylation site from the rabbit b-globin gene and a second polyadenylation site from the SV40 early region. 
Invasive potential of antisense cath-D transfected cells
We next analysed whether inhibition of cath-D expression was correlated with a decrease in the invasive capacity, an important step in the tumor invasion and metastasis process. Matrigel invasion assays established that down-regulation of cath-D did not inhibit the ability of antisense cells to invade across the Matrigel when compared to control clones ( Figure  4 ). These data were also confirmed in four experiments performed in the presence of lower serum concentration (1% FCS+0.1% BSA) in the upper Transwell chamber (data not shown). Taken together, these results suggest that cath-D did not contribute to the invasive potential of MDA-MB-231 cells.
Tumorigenicity and lung colonisation in antisense cath-D transfected cells
To assess the effect of reduction of cath-D expression on tumorigenicity, transfected cells were mixed with Matrigel and subcutaneously injected into athymic mice ( Figure 5 ). In all groups, tumors became apparent 9 days after s.c. injection. However, in the AVA21 and AVA77 groups, tumors grew steadily, whereas tumors from control CB4 and CB6 groups had an exponential growth ( Figure 5a ). Indeed, in the AVA21 and AVA77 antisense groups, the estimated doubling time was 36.1 and 10.4 days, respectively, i.e. significantly longer than CB4 and CB6 control groups of 3.7 days and 1.9 days, respectively (Figure 5a, insert). After 28 days, the tumor sizes from the AVA21 and AVA77 antisense groups reached only approximately 50 mm 3 and 100 mm 3 , respectively, whereas the tumor sizes from the mock-transfected CB4 and CB6 cells reached 200 mm 3 and 500 mm 3 , respectively (Figure 5a ). At sacrifice, the mean tumor weight for the antisense Role of cathepsin-D in breast cancer growth M Glondu et al AVA21 and AVA77 groups was significantly 2.3-fold lower than that noted for the control CB4 and CB6 groups ( Figure 5 ). At autopsy, no spontaneous metastases were detected macroscopically, probably due to the rapid growth of primary tumors. We finally verified the in vivo inhibition of cath-D expression in the antisense AVA21 and AVA77 tumors. Histological sections were stained for human cath-D expression using a monoclonal anti-human cath-D M1G8 antibody ( Figure 6 ). As previously found in cultured cells, a slight cath-D immunostaining was observed in the antisense AVA21 and AVA77 tumor samples ( Figure  6c-d) . By contrast, in the control CB4 and CB6 tumor samples, a strong and punctuated cath-D immunostaining was detected homogeneously in mostly all the cancer cells, localized exclusively in the cytoplasm and mostly concentrated in multivesicular bodies and lysosomal vesicles (Figure 6a,b) . No staining was observed in the control CB4 and CB6 tumor samples with an irrelevant MOPC 21 antibody (Figure 6e,f) . The experimental metastatic potential of the transfected cell lines was also assayed by intravenous injection of cells (Figure 7 ). Five weeks after injection, in the AVA21 and AVA77 antisense groups, mice developed 69+14 and 49+5 lung metastases, respectively (mean+s.e.m.) (Figure 7a ). By contrast, in the CB4 and CB6 control groups, mice developed a significantly higher number of lung metastases, i.e. 414+38 and 235+53, respectively (mean+s.e.m.) (Figure 7a) . Moreover, the total superficial lung metastasis area was also significantly decreased in the antisense groups compared to the control groups (Figure 7b ). These results thus indicate that cath-D enhances both the tumorigenicity and the incidence and growth of metastatic lung colonies of human MDA-MB-231 breast cancer cells.
Discussion
Previous clinical studies in primary breast cancers indicated that cath-D is a pronostic factor predictive for metastasis risk (Rochefort, 1992; Ferrandina et al., 1997; Foekens et al., 1999) , but the causal relationship between over-expression of this protease and metastasis progression remained to be established in human models.
In the present study, we stably transfected the human MDA-MB-231 breast cancer cell line with expression vectors containing, in the antisense orientation, either the complete coding sequence of cath-D or only a 535 bp cDNA fragment complementary to both the 5' translation start site and part of the 3' untranslated regions (Figure 1a ). Although the antisense technique has been widely used within the last few years, defining the best target sequence for antisense RNAs is still a challenge. However, the expression of selected genes has successfully been reduced by antisense RNAs complementary to the 5' translation start site and the coding region, as well as 3' untranslated regions (Wormington, 1986; Kasid et al., 1989) . In our screening procedure, we observed a better mean inhibition (41.8%) of pro-cath-D secretion in clones transfected with the 535 bp fragment antisense cDNA construct as compared to the 26.5% mean reduction observed with clones transfected with the full-sequence antisense vector (Figure 1b) .
Two antisense cell lines expressing 70 -80% less cath-D protein, both intra-and extra-cellularly presented a significant decrease in 3-dimensional in vitro anchorage-independent growth and in growth in vivo both as subcutaneous primary tumors and as experimental lung metastases (Figures 2 -7) . This is the first report demonstrating that cath-D is a rate limiting factor, essential for tumor formation and metastasis development in breast cancer.
Using the antisense approach, a reduction in the malignancy and/or metastatic potential has also been achieved by inhibition of the urokinase plasminogen activator (Haeckel et al., 1998) , matrilysin (Hasegawa et al., 1998) , matrix metalloproteinase-9 (Kondraganti et al., 2000) , cathepsin-B (Mohanam et al., 2001) , and cathepsin-L (Kirschke et al., 2000) , whereas antisense inhibition of TIMPs increased tumorigenicity (Khokha et al., 1989; Castagnino et al., 1998) .
The second line of evidence of this study is that antisense-transfected clones did not show a reduction in in vitro invasiveness when compared with controls ( Figure 4 ). These data indicate that cath-D is more essential for tumor growth than for extracellular matrix invasion. Previous data from our laboratory and other mainly supported this assumption, since mitogenic activity was associated with the exogenous addition of cath-D in MCF-7 breast cancer cells (Vignon et al., 1986; Fusek and Vetvicka, 1994) and with the ectopic expression of cath-D in a rat tumor cell model (Garcia et al., 1990; Liaudet et al., 1995) . Moreover, cath-D mitogenic activity appeared to be a major physiological function of this protease since cathD-/cathD-mice with homozygous gene deletion died due to an absence of tissue renewal (Saftig et al., 1995) . Concerning the possible role of cath-D in tumor invasion, two previous studies that evaluated the relationship between cath-D secretion and invasiveness of MCF7 cells led to divergent conclusions (Johnson et al., 1993; Tedone et al., 1997) .
Inhibition of cath-D in antisense-transfected clones prompted a growth decrease in tri-dimensional matrices (Matrigel, soft agar) (Figures 2 -3) , that was difficult to observe with cell monolayers on plastic using 10 or 2.5% serum concentrations (data not shown). This suggests that cath-D is more essential for anchorage-independent growth and could play a role in the interactions between cell membrane proteins and extra-cellular components. It is generally assumed that culture in 3-dimensional matrix more closely mimics the in vivo situation since matrices might optimize signal transduction between extra-cellular proteins, cell membrane receptors and nuclear machinery components (Bissell et al., 1999) .
The mechanisms of cath-D mitogenic activity have, however, not been elucidated in breast cancer. Previous studies in two cellular models, MCF-7 cells and rat embryo tumor cells, indicated that this mitogenic activity could be due to cath-D action as a protein ligand interacting with a mitogenic receptor (Fusek and Vetvicka, 1994; Glondu et al., 2001 ; reviewed by Rochefort and Liaudet-Coopman, 1999) , or to the proteolytic activity of the enzyme. In rat tumor cells transfected with human cath-D cDNA, two distinct cath-D mitogenic activities were observed as a function of the cell density (Garcia et al., 1990) . At a low cell density with exponentially growing cells, a recent study demonstrated that a mutated cath-D devoid of its catalytic activity still stimulated the exponential growth of cancer cells in tri-dimensional matrices, suggesting cath-D action as a protein ligand (Glondu et al., 2001) . At high cell density, cath-D was found to favor cell growth by decreasing the secretion of unidentified growth inhibitor(s), probably acting via its proteolytic activity (Liaudet et al., 1995) . The later mechanism is also argued by the finding of growth factors (Authier et al., 2002 and references therein) and growth factor receptors (Coyne et al., 2001 ) among the physiological cath-D substrates in human.
In metastatic estrogen-receptor (ER) negative MDA-MB-231 breast cancer cells, the mechanisms of the mitogenic activity of cath-D are unknown and could differ from other cellular models, even ER-positive MCF-7 breast cancer cells. Indeed, there are numerous differences in gene expression between ER-positive and ER-negative breast cancer cell lines that could modify the mechanism of cath-D action. For example, cath-D is up-regulated by estrogen and growth factors in ERpositive MCF-7 cells but is constitutively overexpressed and hyper-secreted in ER-negative MDA-MB-231 cells (reviewed by Garcia et al., 1996) . In addition, pro-cath-D endocytosis is partially mediated by the mannose-6-phosphate/IGFII receptor in MCF-7 cells but is totally independent of this receptor in MDA-MB-231 cells (Laurent-Matha et al., 1998) . Finally, acidification of the culture medium, a critical step in the catalytic activation of secreted pro-cath-D, is lower with MCF-7 cells than with MDA-MB-231 cells (Montcourrier et al., 1997) . Determination of the mechanisms of mitogenic activity of cath-D in our MDA-MB-231 clones could have therapeutical applications since these cells are representative of the subgroup of ER-negative, high-cath-D expressing breast tumors associated with higher metastatic risk in clinical studies (Rochefort, 1992) .
In summary, our present study demonstrate that cath-D is a rate limiting factor for the in vitro growth, tumorigenicity and lung colonization of MDA-MB-231 breast cancer cells. These results provide evidence that cath-D is a good potential target for new breast cancer therapy. The development of such therapy might complement other therapies targeted to genes altered in cancers, and patient selection for this therapy would be guided by the current assay for cath-D in primary breast tumors.
Materials and methods
Generation of the antisense cath-D constructs
The full-length 2 kb human pre-pro-cath-D cDNA isolated from an MCF-7 breast cancer library was cloned in antisense orientation into the EcoRI site of the eucaryotic expression vector pSG1, to produce the pSG1-antisense cath-D (Garcia et al., 1990) . A 1503 bp internal cath-D fragment (nucleotides 253 -1756) was removed by AvaI digestion from the pSG1-antisense cath-D vector, which was then re-ligated to obtain the pSG1-cath-D-AvaI antisense vector (Figure 1a) . Excision of the 1503 bp internal fragment by AvaI was confirmed by EcoRI digestion that detected the 535 bp fragment left of the cath-D cDNA.
Cell lines, transfection, immunoassay and growth assays
The MDA-MB-231 breast cancer cell line was cultured in DEM with 5% FCS. The MDA-MB-231 cell line was cotransfected with a 10-fold excess of control pSG1, pSG1-antisense cath-D or pSG1-antisense cath-D-Ava vectors over the pY3 hygromycin-resistance expression vector by the calcium phosphate-DNA precipitation technique. Colonies growing in the presence of hygromycin B (Invitrogen, 250 mg/ ml) became apparent after 17 -21 days and were subsequently picked for expansion into cell lines. In established clonal cell lines, intracellular and secreted human cath-D were quantified by a cath-D immunoradiometric assay (CIS biointernational) (Garcia et al., 1985) . All experiments using transfected cells were performed from passages 4 -10 and inhibition of human cath-D expression was controlled over this period. For Matrigel outgrowth assays, 50 000 subconfluent cells were harvested and re-suspended in Matrigel (0.2 ml, 6.3 mg/ml) (Becton and Dickinson), an extracellular matrix extracted from an Engelbreth -Holm -Swarm (EHS) mouse tumor, at 48C and then quickly added to a pre-set Matrigel layer in 24-well plates as described (Thompson et al., 1992; Glondu et al., 2001) . The top Matrigel cell layers were gelled at 378C for 30 min, and then covered with culture medium containing 10% FCS (0.5 ml). At various times, cells growing in Matrigel were recovered with 3 ml of Matrisperse (Becton and Dickinson), fixed with methanol and their DNA content was determined by the diaminobenzoic acid fluorescence assay (Vignon et al., 1986) . Soft agar assays were performed using 6000 cells per 24 well-plate (Fang et al., 1992) .
Invasion assay
A suspension of 300 000 cells was layered in the upper compartment of a Transwell (Costar, Cambridge, MA, USA) on a polycarbonate filter (8 mm pore size) precoated with 30 mg of Matrigel basement membrane. In the lower compartment, the DEM medium containing 10% FCS was supplemented with 30 mg/ml fibronectin (Sigma) as chemoattractant. After 24 h at 378C, cells migrating through the filter were evaluated with the mitochondrial deshydrogenase enzymatic assay using 3(4,5-dimethyl-thiazol-2-yl)2,5-diphenol tetrazolium bromide (MTT) and OD 540nm was determined, as previously described (Platet et al., 1998) .
Tumor growth
For tumor growth in animals, cells were trypsinized, washed, centrifuged, re-suspended in cold PBS (GibcoBRL) and mixed with an equal volume of cold Matrigel (10 mg/ml). A total volume of 0.3 ml containing (400 000) cells was subcutaneously injected under the mammary fat-pad of 6-week-old Balb/c female nude mice (IFFA CREDO). Injected mice were examined every 2 or 3 days for tumor appearance and tumor volumes were estimated from the product of the three perpendicular diameters. After 28 days, animals were sacrified and tumors were weighed.
Cath-D immunostaining. Tumor samples were fixed in 10% buffered formalin solution overnight, embedded in paraffin, and sectioned. Histological tumors sections were treated with anti-human cath-D M1G8 mouse monoclonal antibody at 3 mg/ml (Cis Bio International, Gif-sur-Yvette, France) or an irrelevant MOPC 21 monoclonal antibody of the same immunoglobulin subclass (IgG 1 ) (Letton Bionetics Inc, Kensington, MA, USA) as previously described (Roger et al., 1994) . Staining was revealed using a standard avidin biotin enhanced immunoperoxidase technique (ABC Kit Vectastain, Vector Labs, Inc, Burlingame, CA, USA).
Experimental lung metastases assay
The ability of transfected cell lines to develop experimental lung metastases was assayed following injection of a monodisperse tumor cell suspension (300 000 cells per 0.2 ml PBS) with a viability greater than 95% into the lateral tail vein of 6-week-old Balb/c female nude mice (Garcia et al., 1992) . Five weeks after cell inoculation, the mice were killed and the lungs removed, rinsed in saline, and fixed in Bouin's solution. The number and area of visible lung nodules were determined by examination under a dissecting microscope equipped with a millimeter-squared eye grid. The neoplastic nature of these nodules was confirmed by histological examination.
